Datapoint: Kadmon Holdings Scores First FDA Approval

The FDA last week approved Kadmon Holdings’ Rezurock for the treatment of chronic graft-versus-host disease, making the drug both Kadmon’s first-ever FDA approved drug, and the first ROCK2 inhibitor in the graft-versus-host market basket. Among the most advantaged therapies for graft-versus-host disease are Johnson & Johnson and AbbVie’s Imbruvica, which holds covered or better status for 73% of all insured lives under the pharmacy benefit, Incyte Corp.’s Jakafi (72%) and Amgen’s Enbrel (70%).

SOURCE: MMIT Analytics, as of 7/19/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today